No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concerns require Pfizer to scupper two additional studies of its Phase III tanezumab, casting doubt on an entire class of new pain drugs.
You may also be interested in...
Anti-NGF Drugs Clinical Holds Could Depend On What FDA Panel Thinks Of Standard Of Care
FDA’s Arthritis Advisory Committee will review troubling reports that the drugs, meant to relieve chronic pain from osteoarthritis and other diseases, may also destroy patients’ joints.
Anti-Nerve Growth Factor Developers Face Go/No-Go Recommendation From Advisory Panel
FDA sets March 12 as date for the Arthritis Advisory Committee to weigh in on whether safety issues are a barrier to development of anti-NGF compounds as analgesics. Developers’ trials are on hold while FDA considers the potential for adverse effects seen in osteoarthritis patients taking the monoclonal antibodies for pain.
Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel
The entire class of biologics has fallen under suspicion of worsening the very condition it is supposed to treat, and FDA has imposed clinical holds on ongoing trials.